Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

(2013) C. Roux et al.   BONE

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab

(2013) Tony M Keaveny et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy

(2013) Chris Recknor et al.   OBSTETRICS AND GYNECOLOGY

Psychometric Properties of the Osteoporosis-Specific Morisky Medication Adherence Scale in Postmenopausal Women with Osteoporosis Newly Treated with Bisphosphonates

(2012) Kristi Reynolds et al.   ANNALS OF PHARMACOTHERAPY

Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data

(2012) David W. Dempster et al.   CLINICAL THERAPEUTICS

Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody

(2011) Paul J. Kostenuik et al.   BONE

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

(2011) Michael S. Ominsky et al.   BONE

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

(2011) Michael R McClung et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

(2011) Matthew Austin et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk

(2011) S. Boonen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System

(2011) J. Devine et al.   OSTEOPOROSIS INTERNATIONAL

Adoption of Once-monthly Oral Bisphosphonates and the Impact on Adherence

(2010) Becky A. Briesacher et al.   AMERICAN JOURNAL OF MEDICINE

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

(2010) H.K. Genant et al.   BONE

Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate

(2010) Ego Seeman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009

(2010) S. Lee et al.   OSTEOPOROSIS INTERNATIONAL

Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe

(2009) Ethel S. Siris et al.   AMERICAN JOURNAL OF MEDICINE

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

(2009) David L Kendler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis

(2009) F.-E. Cotté et al.   OSTEOPOROSIS INTERNATIONAL

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization

(2008) J. A. Sunyecz et al.   OSTEOPOROSIS INTERNATIONAL